Filip Dubovsky, M.D.

Filip Dubovsky, M.D.

Former President, Research & DevelopmentatNovavax· In proxies 2023–2024

Pay in FY2024-20% from the year before · Novavax stock +67.5% the same year

Filip Dubovsky, M.D. was paid $1.6M in FY2024 (Dec), down 20%. Novavax stock rose 67.5% that year.

Pay$100 in the stock at the end of FY22 → $78
Pay is from the Summary Compensation Table of each Novavax proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NovavaxPublic company · 3 yr
    • Former President, Research & Development2023 – Present · 3 yrStock in role +16%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?